Binimetinib

Small molecule

Also known as MEK162

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, Melanoma

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
CA
  • MEKTOVI (binimetinib) is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test. Clinical data supporting the use of MEKTOVI in the treatment of patients with BRAF V600 mutations are limited to patients with V600E or V600K mutations.
Product first approved 2021Health Canada
JP
  • Unresectable melanoma with a BRAF mutation, in combination with encorafenib (MEKTOVI tablets)
Product first approved 2019ono-pharma.com
EU
  • MelanomaBinimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.Non-small cell lung cancer (NSCLC)Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600E mutation.
Product first approved 2018EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (8)
Melanoma
NCT05270044 · Pierre Fabre Medicament
2022-05-02 – 2035-05-02 · Melanoma
What this study did
NCT04657991 · Pfizer
2021-01-15 – 2026-10-30 · Melanoma
What this study did
Other / comorbidity
NCT05615818 · UNICANCER
2024-07-18 – 2028-06 · Biliary Tract Neoplasms
What this study did
NCT03803553 · Massachusetts General Hospital
2020-04-16 – 2027-12 · Metastatic Colon Cancer, Stage III Colon Cancer
What this study did
NCT01849874 · Pfizer
2013-06-27 – 2022-08-23 · Low-grade Serous Ovarian Cancer, Low-grade Serous Fallopian Tube Cancer, Low-grade Serous Peritoneal Cancer
What this study did
Phase 2 (54)
Melanoma
NCT03563729 · Inge Marie Svane
2018-06-06 – 2028-06-06 · Malignant Melanoma
What this study did
NCT04598009 · University of California, San Francisco
2021-03-03 – 2028-05-31 · Melanoma Stage III, Melanoma Stage IV
What this study did
NCT05097378 · CCTU- Cancer Theme
2023-02-27 – 2028-05-31 · Melanoma, Cancer
What this study did
NCT06887088 · Grupo Español Multidisciplinar de Melanoma
2025-05-29 – 2028-01 · Melanoma BRAF V600E/K Mutated, Melanoma and Brain Metastases
What this study did
NCT05170334 · H. Lee Moffitt Cancer Center and Research Institute
2021-12-15 – 2028-01 · Metastatic Uveal Melanoma
What this study did
NCT02465060 · National Cancer Institute (NCI)
2015-08-17 – 2027-12-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
What this study did
NCT02910700 · M.D. Anderson Cancer Center
2016-12-09 – 2027-12-08 · Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7, Unresectable Melanoma
What this study did
NCT04511013 · SWOG Cancer Research Network
2021-01-06 – 2027-06-30 · Acral Lentiginous Melanoma, Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Cutaneous Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Metastatic Mucosal Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
What this study did
NCT04074096 · UNICANCER
2022-09-05 – 2027-03-27 · Malignant Melanoma, BRAF V600 Mutation, Brain Metastases
What this study did
NCT05026983 · M.D. Anderson Cancer Center
2021-12-27 – 2027-02-02 · Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8
What this study did
NCT03235245 · European Organisation for Research and Treatment of Cancer - EORTC
2018-10-30 – 2027-01 · Unresectable Stage III Melanoma, Stage IV Melanoma
What this study did
NCT05767879 · Leiden University Medical Center
2022-01-01 – 2026-01-01 · Melanoma Stage III, In-Transit Metastasis of Cutaneous Melanoma
What this study did
NCT05304546 · Dr. Ronnie Shapira
2023-09-05 – 2025-07-17 · Malignant Melanoma, Metastatic Melanoma, Immunotherapy, BRAF V600E, Malignant Melanoma Stage IV
What this study did
NCT04221438 · ECOG-ACRIN Cancer Research Group
2021-09-22 – 2025-01-31 · Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8, Recurrent Cutaneous Melanoma
What this study did
NCT04375527 · Jonsson Comprehensive Cancer Center
2020-12-03 – 2024-11-22 · Clinical Stage III Cutaneous Melanoma AJCC V8, Clinical Stage IV Cutaneous Melanoma AJCC V8, Locally Advanced Cutaneous Melanoma, Metastatic Cutaneous Melanoma, Pathologic Stage III Cutaneous Melanoma AJCC V8, Pathologic Stage IIIA Cutaneous Melanoma AJCC V8, Pathologic Stage IIIB Cutaneous Melanoma AJCC V8, Pathologic Stage IIIC Cutaneous Melanoma AJCC V8, Pathologic Stage IIID Cutaneous Melanoma AJCC V8, Pathologic Stage IV Cutaneous Melanoma AJCC V8, Unresectable Cutaneous Melanoma
What this study did
NCT02631447 · Fondazione Melanoma Onlus
2016-11-14 – 2024-05-31 · Metastatic Melanoma
What this study did
NCT03898908 · Grupo Español Multidisciplinar de Melanoma
2019-07-18 – 2023-07-31 · Metastatic Melanoma, Brain Metastases
What this study did
NCT01320085 · Pfizer
2011-03-24 – 2023-02-06 · BRAF or NRAS Mutant Metastatic Melanoma
What this study did
NCT02159066 · Pfizer
2014-07-23 – 2023-01-10 · Melanoma
What this study did
NCT02263898 · Jonsson Comprehensive Cancer Center
2015-01 – 2020-12 · Recurrent Melanoma, Stage IV Melanoma
What this study did
NCT02094872 · Yale University
2014-05 – 2018-12 · Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT04526782 · Intergroupe Francophone de Cancerologie Thoracique
2021-01-19 – 2027-03 · Non Small Cell Lung Cancer, BRAF V600E
What this study did
NCT05195632 · Pierre Fabre Medicament
2022-06-02 – 2026-12-14 · Non-Small Cell Lung Cancer
What this study did
NCT04735068 · Abramson Cancer Center at Penn Medicine
2021-04-09 – 2023-12-31 · Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors
What this study did
NCT02276027 · Novartis Pharmaceuticals
2015-01-20 – 2019-10-15 · Adenocarcinoma Lung Cancer; Squamous Cell Lung Carcinoma
What this study did
Other / comorbidity
NCT05564377 · National Cancer Institute (NCI)
2023-04-07 – 2030-07-01 · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
What this study did
NCT04324112 · National Cancer Institute (NCI)
2020-10-28 – 2029-06-30 · Hairy Cell Leukemia
What this study did
NCT06207656 · Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
2024-04-16 – 2029-04-01 · Colorectal Cancer
What this study did
NCT04061980 · Providence Health & Services
2020-10-30 – 2028-12-30 · BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage IV Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v8, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v8
What this study did
NCT06159478 · National Cancer Center, Japan
2023-06-30 – 2028-09-30 · Low-grade Glioma, Pancreatic Cancer
What this study did
NCT05554367 · National Cancer Institute (NCI)
2023-12-13 – 2028-08-26 · Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT04322383 · National Cancer Institute (NCI)
2021-01-07 – 2028-07-31 · Hairy Cell Leukemia
What this study did
NCT05564403 · National Cancer Institute (NCI)
2024-02-09 – 2027-10-15 · Advanced Biliary Tract Carcinoma, Advanced Gallbladder Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Recurrent Biliary Tract Carcinoma, Recurrent Gallbladder Carcinoma, Recurrent Intrahepatic Cholangiocarcinoma, Stage III Distal Bile Duct Cancer AJCC v8, Stage III Gallbladder Cancer AJCC v8, Stage III Hilar Cholangiocarcinoma AJCC v8, Stage III Intrahepatic Cholangiocarcinoma AJCC v8, Stage IV Distal Bile Duct Cancer AJCC v8, Stage IV Gallbladder Cancer AJCC v8, Stage IV Hilar Cholangiocarcinoma AJCC v8, Stage IV Intrahepatic Cholangiocarcinoma AJCC v8, Unresectable Biliary Tract Carcinoma, Unresectable Gallbladder Carcinoma, Unresectable Intrahepatic Cholangiocarcinoma
What this study did
NCT05286788 · Nationwide Children's Hospital
2023-04-10 – 2027-04-10 · Adamantinous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma
What this study did
NCT04439344 · National Cancer Institute (NCI)
2016-05-31 – 2027-03-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
What this study did
NCT03971409 · Laura Huppert, MD, BA
2019-07-08 – 2027-01-31 · Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Invasive Breast Carcinoma, Recurrent Breast Carcinoma, Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma
What this study did
NCT03839342 · University Health Network, Toronto
2019-06-07 – 2026-12 · Solid Tumor
What this study did
NCT05554354 · National Cancer Institute (NCI)
2024-09-13 – 2025-04-04 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma
What this study did
NCT05510895 · AIO-Studien-gGmbH
2022-09-01 – 2025-01-31 · Colorectal Cancer, Colon Cancer, BRAF V600E, BRAF V600 Mutation, Localized Cancer
What this study did
NCT03981614 · Academic and Community Cancer Research United
2019-10-29 – 2024-07-02 · Metastatic Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8, Unresectable Carcinoma
What this study did
NCT05097599 · Strata Oncology
2022-04-29 – 2024-06-12 · Cancer, Advanced Solid Tumor
What this study did
NCT03231306 · University of Alabama at Birmingham
2017-11-28 – 2024-04-17 · Neurofibromatosis Type 1, Plexiform Neurofibroma
What this study did
NCT03475004 · University of Colorado, Denver
2018-09-17 – 2024-02-12 · Colorectal Cancer, Metastatic Cancer
What this study did
NCT04390243 · Academic and Community Cancer Research United
2020-11-16 – 2023-11-01 · Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT03973918 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2019-07-29 – 2023-10-01 · High Grade Glioma, BRAF V600E, BRAF V600K, Anaplastic Astrocytoma, Anaplastic Pleomorphic Xanthoastrocytoma, Gliosarcoma, Glioblastoma
What this study did
NCT03693170 · Pierre Fabre Medicament
2019-01-17 – 2023-04-27 · BRAF V600E-mutant Metastatic Colorectal Cancer
What this study did
NCT02834364 · University of Heidelberg Medical Center
2016-06 – 2023-03-29 · Relapsed or Refractory Multiple Myeloma, Patients With BRAFV600 E or BRAFV600K Mutation
What this study did
Phase 1/2 (23)
Melanoma
NCT03947385 · IDEAYA Biosciences
2019-06-28 – 2027-06-15 · Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer, Other Solid Tumors
What this study did
NCT05340621 · OnKure, Inc.
2022-05-11 – 2025-01-29 · RAS Mutation, NRAS Gene Mutation, Melanoma
What this study did
NCT04720768 · Peter MacCallum Cancer Centre, Australia
2020-06-04 – 2024-12-04 · Melanoma, Metastasis
What this study did
NCT02902042 · Prof. Dr. med. Dirk Schadendorf
2018-04-24 – 2020-11-30 · Malignant Melanoma
What this study did
NCT01781572 · Pfizer
2013-06 – 2018-02-20 · Locally Advanced or Metastatic NRAS Mutant Melanoma
What this study did
NCT01801358 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2013-08 – 2015-05 · Uveal Melanoma
What this study did
NCT01562899 · Pfizer
2012-08-27 – 2015-04-01 · Metastatic Pancreatic Adenocarcinoma, BRAF Mutated Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT04585815 · Pfizer
2020-11-10 – 2024-10-29 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04720976 · Allist Pharmaceuticals, Inc.
2021-03-23 – 2023-12-19 · Solid Tumor, NSCLC
What this study did
NCT04292119 · Massachusetts General Hospital
2020-05-01 – 2023-03-01 · Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement, Relapsed Cancer, MET Amplification, Resistant Cancer, NSCLC
What this study did
Other / comorbidity
NCT05080621 · Deciphera Pharmaceuticals, LLC
2021-11 – 2027-05 · Gastrointestinal Stromal Tumors
What this study did
NCT01991379 · Memorial Sloan Kettering Cancer Center
2013-11 – 2026-11 · Gastrointestinal Stromal Tumor (GIST)
What this study did
NCT02285439 · Children's Hospital Los Angeles
2016-05-04 – 2025-08-01 · Low-Grade Gliomas, Malignant Neoplasms, Brain, Soft Tissue Neoplasms
What this study did
NCT04494958 · Fundacion Oncosur
2020-11-18 – 2023-12-14 · Triple Negative Breast Cancer
What this study did
NCT03843775 · Memorial Sloan Kettering Cancer Center
2019-02-14 – 2023-09-02 · Advanced BRAF Mutant Cancers
What this study did
NCT01543698 · Pfizer
2012-05-28 – 2023-03-09 · Solid Tumors Harboring a BRAF V600 Mutation
What this study did
NCT03106415 · Mayo Clinic
2017-09-27 – 2022-05-19 · Breast Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage III Breast Cancer AJCC v7, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
What this study did
NCT03637491 · Pfizer
2018-08-15 – 2021-02-02 · Pancreatic Cancer
What this study did
NCT02089230 · M.D. Anderson Cancer Center
2014-08-27 – 2019-06-05 · Leukemia
What this study did
NCT01828034 · Memorial Sloan Kettering Cancer Center
2013-04 – 2019-05-30 · Advanced Biliary Tract Carcinoma
What this study did
NCT02773459 · Seoul National University Hospital
2016-04 – 2019-01-07 · Biliary Tract Cancer
What this study did
NCT01927341 · Pfizer
2013-11-19 – 2016-01-25 · Metastatic Colorectal Cancer
What this study did
Phase 1 (41)
Melanoma
NCT04903119 · Rina Plattner
2022-06-01 – 2030-06-01 · Metastatic Melanoma, BRAF Gene Mutation
What this study did
NCT04741997 · H. Lee Moffitt Cancer Center and Research Institute
2021-05-24 – 2027-04 · Melanoma Stage III, Melanoma Stage IV, BRAF V600 Mutation
What this study did
NCT03543969 · H. Lee Moffitt Cancer Center and Research Institute
2018-06-14 – 2026-12 · Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
What this study did
NCT03864042 · Pfizer
2018-01-02 – 2023-05-29 · Advanced Solid Tumors, Metastatic Melanoma
What this study did
NCT04759846 · Pierre Fabre Medicament
2021-01-21 – 2023-05 · BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma, Hepatic Impairment
What this study did
NCT05810740 · Pierre Fabre Medicament
2022-08-31 – 2023-01-18 · Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
What this study did
NCT05103891 · Pierre Fabre Medicament
2021-09-03 – 2021-11-29 · Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
What this study did
Non-Small Cell Lung Cancer
NCT04913285 · Pierre Fabre Medicament
2021-08-04 – 2029-03-30 · Solid Tumor, Adult, Non-small Cell Lung Cancer, Melanoma
What this study did
NCT05355701 · Pfizer
2022-07-05 – 2027-08-31 · Melanoma, Non-Small-Cell Lung Cancer, Thyroid Cancer, Glioma, Advanced Colorectal Cancer (Part 1)
What this study did
NCT03991819 · University Health Network, Toronto
2019-09-20 – 2026-12 · Non-small Cell Carcinoma
What this study did
NCT04870034 · Roswell Park Cancer Institute
2024-01-15 – 2026-09-30 · Colorectal Carcinoma, Lung Adenocarcinoma, Malignant Solid Neoplasm, Pancreatic Carcinoma
What this study did
NCT04892017 · Deciphera Pharmaceuticals, LLC
2021-06-15 – 2026-03-30 · Non-Small Cell Lung Cancer, Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT03170206 · Dana-Farber Cancer Institute
2017-05-31 – 2025-12-31 · Lung Cancer
What this study did
NCT04543188 · Pfizer
2021-01-08 – 2024-03-20 · Malignant Melanoma, Carcinoma, Non-Small-Cell Lung, Brain Neoplasms, Primary, Brain Neoplasms, Malignant Neoplasms
What this study did
NCT04965818 · Taiho Oncology, Inc.
2021-09-20 – 2023-09-21 · Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
What this study did
NCT04005144 · University of California, San Francisco
2020-02-25 – 2022-10-01 · ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Progressive Disease, ROS1 Gene Rearrangement, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer
What this study did
NCT02964689 · Swiss Cancer Institute
2017-04-12 – 2021-07-02 · Advanced Non-small Cell Lung Cancer, KRAS Gene Mutation, Lung Cancer
What this study did
NCT01859026 · H. Lee Moffitt Cancer Center and Research Institute
2013-12-30 – 2019-08-22 · Lung Cancer, Non-Small Cell Lung Cancer
What this study did
NCT02451865 · Jonsson Comprehensive Cancer Center
2016-06 – 2019-06 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05111561 · National Cancer Institute (NCI)
2022-08-02 – 2027-03-14 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Triple-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
What this study did
NCT04132505 · M.D. Anderson Cancer Center
2019-10-22 – 2026-03-24 · Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT04800822 · Pfizer
2021-03-17 – 2024-06-19 · Solid Tumor
What this study did
NCT02613650 · University of Utah
2016-08-19 – 2022-12-21 · Advanced KRAS Positive Metastatic Colorectal Cancer
What this study did
NCT04044430 · University of California, San Francisco
2020-08-31 – 2022-07-31 · Metastatic Colon Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Stage III Colon Cancer, Stage III Colorectal Cancer, Stage III Rectal Cancer, Stage IIIA Colon Cancer, Stage IIIA Colorectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Colon Cancer, Stage IIIB Colorectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIC Colorectal Cancer, Stage IIIC Rectal Cancer, Stage IV Colon Cancer, Stage IV Colorectal Cancer, Stage IV Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Colorectal Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Colorectal Cancer, Stage IVB Rectal Cancer, Stage IVC Colon Cancer, Stage IVC Colorectal Cancer, Stage IVC Rectal Cancer
What this study did
NCT03158103 · Memorial Sloan Kettering Cancer Center
2017-04-15 – 2021-04-28 · Gastrointestinal Stromal Tumor (GIST)
What this study did
NCT02185690 · University Health Network, Toronto
2017-03-07 – 2019-07-04 · Lungcancer
What this study did
NCT02510001 · University of Oxford
2014-11 – 2018-12-03 · Solid Tumor, Colorectal Cancer
What this study did
NCT01469130 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2011-11 – 2018-02-01 · Advanced Solid Tumor
What this study did
NCT02041481 · City of Hope Medical Center
2014-07-16 – 2018-01-19 · Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
What this study did
NCT01363232 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2011-08 – 2017-12-18 · Advanced Solid Tumors, Selected Solid Tumors
What this study did
NCT02049801 · Bruno C. Medeiros
2014-12 – 2017-11-01 · Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
What this study did
NCT01449058 · Array BioPharma
2012-03 – 2017-08-15 · Advanced and Selected Solid Tumors, AML, High Risk and Very High Risk MDS
What this study did
NCT02050815 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2014-03 – 2016-08-26 · Hepatic Impairment
What this study did
NCT01649336 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2012-07 – 2016-03 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
What this study did
NCT02105350 · University Health Network, Toronto
2015-06 – 2015-06 · Biliary Tract Carcinoma, Gallbladder Carcinoma
What this study did
NCT01352273 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2011-06 – 2013-09 · Advanced Solid Tumors
What this study did
NCT01337765 · Pfizer
2011-07-08 – 2013-03-22 · Unspecified Adult Solid Tumor, Protocol Specific, Solid Tumor
What this study did
NCT00959127 · Array Biopharma, now a wholly owned subsidiary of Pfizer
2009-08 – 2013-01 · Advanced Solid Tumors, Advanced or Metastatic Biliary Cancer, Metastatic Colorectal Cancer
What this study did
Phase 4 (2)
Melanoma
Other / comorbidity
Early phase / not applicable (1)
Other / comorbidity
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Binimetinib: this drugApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Intismeran AutogenePhase 3VaccinePatient-specific tumor neoantigens (personalized, up to 34 per patient)not yet gradedNo reviewed efficacy summary in this indication
RelatlimabPhase 3Monoclonal antibodyLAG-3Partial signal
NCT04623775: Part 2 objective response rate by BICR (RECIST 1.1): nivolumab + relatlimab + chemotherapy 50.6% (90% CI 43.8 to 57.4, n=158) vs nivolumab + chemotherapy 43.0% (90% CI 36.2 to 50.1, n=151); odds ratio 1.39 (90% CI 0.94 to 2.05). The Part 1 co-primary (TRAEs leading to discontinuation within 12 weeks) compares two relatlimab regimens: 5.6% vs 12.1% (CT.gov posted results). missed
LNS8801
Phase 2/3(overall)
Small moleculeGPER (G protein-coupled estrogen receptor)not yet gradedNo reviewed efficacy summary in this indication
ResiquimodPhase 2/3Small moleculeToll-like receptor 7 and 8 (TLR7/8)not yet gradedNo reviewed efficacy summary in this indication
LuvometinibPhase 2Small moleculeMEK1/2not yet gradedNo reviewed efficacy summary in this indication
Vusolimogene Oderparepvec (Tudriqev)Phase 2Oncolytic virusNo discrete molecular targetnot yet gradedNo reviewed efficacy summary in this indication
EvalstotugPhase 1/2Biologic (subtype unspecified)CTLA-4not yet gradedNo reviewed efficacy summary in this indication
OBX-115Phase 1/2Cell therapyIL-15 receptor signalingnot yet gradedNo reviewed efficacy summary in this indication
VSV-IFNβ-NISPhase 1/2Oncolytic virusOncolytic VSV expressing interferon-beta and NISnot yet gradedNo reviewed efficacy summary in this indication
CRX100Phase 1Cell therapyCell-based oncolytic virus immunotherapynot yet gradedNo reviewed efficacy summary in this indication
HS-IT101Phase 1Cell therapyAutologous tumor neoantigens (polyclonal, patient-specific)not yet gradedNo reviewed efficacy summary in this indication
NaporafenibDiscontinuedSmall moleculePan-RAFWeak signal
NCT02607813: 142 patients were treated across the naporafenib dose-escalation (n = 87), naporafenib plus spartalizumab dose-escalation (n = 12) and dose-expansion (n = 43) arms. The maximum tolerated and recommended dose for single-agent naporafenib was 600 mg twice daily. Five patients in the naporafenib escalation arm had 7 dose-limiting toxicities, including decreased platelet count at 1200 mg once daily, neuralgia, maculopapular rash and pruritus at 600 mg twice daily, and increased blood bilirubin, hyponatremia and peripheral sensory neuropathy at 800 mg twice daily.

Large race: only the 73 furthest-along competitors are listed; 537 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(26 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Binimetinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
November 2026 (1)
Phase 1/2Gastrointestinal Stromal Tumor (GIST)Active not recruiting
Est. primary completion 2026-11 · NCT01991379 · CT.gov ↗
What to watch
December 2026 (2)
Phase 2Solid TumorActive not recruiting
Est. primary completion 2026-12 · NCT03839342 · CT.gov ↗
What to watch
Phase 3Metastatic Colon Cancer, Stage III Colon CancerActive not recruiting
Est. primary completion 2026-12 · NCT03803553 · CT.gov ↗
What to watch
2027 (14)
January 2027 (2)
Phase 1/2MelanomaRecruiting
Est. primary completion 2027-01-29 · NCT03947385 · CT.gov ↗
What to watch
Phase 2Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer …Active not recruiting
Est. primary completion 2027-01-31 · NCT03971409 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2027-02-02 · NCT05026983 · CT.gov ↗
What to watch
March 2027 (2)
Phase 1Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm …Recruiting
Est. primary completion 2027-03-14 · NCT05111561 · CT.gov ↗
What to watch
Phase 3MelanomaActive not recruiting
Est. primary completion 2027-03-31 · NCT05270044 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1MelanomaRecruiting
Est. primary completion 2027-04 · NCT04741997 · CT.gov ↗
What to watch
Phase 2Adamantinous Craniopharyngioma, Recurrent Adamantinomatous CraniopharyngiomaRecruiting
Est. primary completion 2027-04-10 · NCT05286788 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2027-05-31 · NCT04598009 · CT.gov ↗
What to watch
June 2027 (2)
Phase 3Biliary Tract NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05615818 · CT.gov ↗
What to watch
Phase 2MelanomaRecruiting
Est. primary completion 2027-06-30 · NCT04511013 · CT.gov ↗
What to watch
August 2027 (1)
Phase 1Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-08-31 · NCT05355701 · CT.gov ↗
What to watch
December 2027 (3)
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-08 · NCT02910700 · CT.gov ↗
What to watch
Phase 2BRAF NP_004324.2:p.V600M, BRAF V600E Mutation Present, Metastatic Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma …Active not recruiting
Est. primary completion 2027-12-30 · NCT04061980 · CT.gov ↗
What to watch
Phase 2MelanomaActive not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
2028 (6)
January 2028 (1)
Phase 2MelanomaRecruiting
Est. primary completion 2028-01 · NCT06887088 · CT.gov ↗
What to watch
February 2028 (1)
Phase 2Low-grade Glioma, Pancreatic CancerRecruiting
Est. primary completion 2028-02-28 · NCT06159478 · CT.gov ↗
What to watch
April 2028 (1)
Phase 2Hairy Cell LeukemiaRecruiting
Est. primary completion 2028-04-30 · NCT04322383 · CT.gov ↗
What to watch
July 2028 (1)
Phase 1MelanomaRecruiting
Est. primary completion 2028-07-01 · NCT04903119 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8 …Active not recruiting
Est. primary completion 2028-08-26 · NCT05554367 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-11-30 · NCT04913285 · CT.gov ↗
What to watch
2029 (2)
April 2029 (1)
Phase 2Colorectal CancerRecruiting
Est. primary completion 2029-04-01 · NCT06207656 · CT.gov ↗
What to watch
July 2029 (1)
Phase 4Solid TumorsRecruiting
Est. primary completion 2029-07-31 · NCT05203172 · CT.gov ↗
What to watch
2030 (1)
July 2030 (1)
Phase 2Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8 …Recruiting
Est. primary completion 2030-07-01 · NCT05564377 · CT.gov ↗
What to watch

See the full readout calendar ↗